Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19
Background. Severe forms of COVID-19 are associated with the development of a cytokine storm that is characterized by an increased secretion of anti-inflammatory cytokines. Thus, one of the leading strategies of treatment for patients with severe forms of COVID-19 is a decrease in the concentration...
Main Authors: | O. V. Zhukova, A. L. Khokhlov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2021-04-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/483 |
Similar Items
-
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
by: Olivier Hermine, et al.
Published: (2022-04-01) -
Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
by: Carlos K. H. Wong, et al.
Published: (2022-05-01) -
Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
by: Fabrice Camou, et al.
Published: (2022-09-01) -
Constituents, pharmacological activities, pharmacokinetic studies, clinical applications, and safety profile on the classical prescription Kaixinsan
by: Liping Chen, et al.
Published: (2024-02-01) -
Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
by: Konstantinos Pagkratis, et al.
Published: (2022-06-01)